back to US directory
us clinical guidance

Adult valvular heart disease

US evaluation, staging, surveillance and multidisciplinary intervention planning for adult valvular heart disease.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or known native or prosthetic valvular heart disease. The ACC/AHA stages integrate symptoms, anatomy, severity, ventricular response and pulmonary circulation. Congenital lesions, infective endocarditis and pregnancy require additional condition-specific guidance.
sources for this section:ACC/AHA valves 2020

The Bottom Line

  • Stage valve disease from symptoms, valve anatomy, severity and the response of the ventricles and pulmonary circulation rather than using auscultation alone.
  • Correlate history and examination with ECG, chest radiography and transthoracic echocardiography; investigate discordance with appropriate advanced noninvasive or invasive testing.
  • Base surveillance and intervention on the affected valve, stage, symptoms, ventricular size and function, pulmonary pressure, operative risk and expected benefit.
  • Use a multidisciplinary valve team for severe disease and complex decisions about surgical versus transcatheter repair or replacement.
  • For AF with valve disease, anticoagulant choice depends on the specific lesion and prosthesis; mechanical prostheses and rheumatic mitral stenosis are important exceptions to routine DOAC use.
sources for this section:ACC/AHA valves 2020

Practical clinical workflow

1
Define symptoms, prior rheumatic or congenital disease, infection risk, radiation, surgery and prosthesis history; examine for murmurs, congestion and low-output signs.
2
Obtain transthoracic echocardiography to identify valve anatomy, severity and cardiac response, then reconcile the findings with clinical status.
3
Use transesophageal echocardiography, CT, cardiac MRI, stress testing or catheterization when the first-line assessment is discordant or intervention planning requires it.
4
Assign stage and the source-defined follow-up interval; optimize associated hypertension, coronary disease, heart failure and atrial fibrillation.
5
Refer severe or symptomatic disease, ventricular deterioration or prosthetic dysfunction to a comprehensive valve team before irreversible consequences develop.
sources for this section:ACC/AHA valves 2020

Safety boundaries and escalation

  • Syncope, rest dyspnea, pulmonary edema, chest pain with severe stenosis, hypotension, acute severe regurgitation or suspected prosthetic dysfunction needs urgent specialist or emergency assessment.
  • Fever or bacteremia with a native or prosthetic valve raises infective-endocarditis concerns and follows a separate urgent diagnostic pathway.
  • Do not start or switch anticoagulation for a mechanical valve or rheumatic mitral stenosis without the specific guideline and current label.
  • Pregnancy can materially change hemodynamic risk, imaging and intervention timing; involve a cardio-obstetrics team early.
sources for this section:ACC/AHA valves 2020

Localization

Use ACC/AHA valve stages, US transcatheter-device indications and FDA labeling. Local structural-heart capability and insurer authorization influence planned procedures, but acute instability takes priority.
sources for this section:ACC/AHA valves 2020

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2020 Guideline for the Management of Patients With Valvular Heart DiseaseDOI 10.1161/CIR.0000000000000923 路 published 2020-12-17 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.